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ABSTRACT
Background. The measurement of brachial 
pressure (BP) has passed been on for ages, 
but the central pressure detection could 
only be possible with invasive techniques, 
until recently non-invasive and modern 
technology was introduced into the clini-
cal setting. Studies described that the in-
crease in central blood pressure (CBP) is 
an indicator of future cardiovascular or 
target organ damage. Compared with the 
general population, cardiorenal morbidity 
is much higher in patients with resistant 
hypertension (RH).  We investigated for 
the first time the value of CBP and pulse 
wave velocity (PWV) in a group of RH pa-
tients. 
Materials and Methods. Data from 80 pa-
tients with RH (resistance to 3 or more 
drugs, one is diuretic) without chronic 
kidney disease, at University hospital 
Merkur, Zagreb from the period of June 
2017 to January 2018 were analysed. The 
pulse wave velocity (PWV), mean arterial 
pressure (MAP), vessels age (older than 
biological age), pulse pressure (PP), central 
blood pressure (CBP), brachial pressure 
(BP) were evaluated using the noninvasive 
Agedio B900 device (Germany).
Results. The median age was 58.75 (SD-
15.3). 27 (35%) of patients were male 
(avg 53.9 y). BP and CBP were elevated 
in all RH patients (53 F/27M). The dif-
ference between the median value of 
BP (145.9/90.52mmHg, F=146.4/89.5, 
M=145/92) and CBP (132.16/91.78mmHg, 
F=132/90, M 131/94) was statistically sig-
nificant for systolic BP (p<0.01). The mean 
value of the total measured PWV value was 
higher than reference for age in all RH and 
was 8.84 m/s. The mean value of PP and 
MAP was higher than reference (60.11 and 
123,87 mmHg). The difference between sex 
was statistically significant higher for PWV 
in females than males (M/F= 8.1/9.2m/s, 
p<0.01). The difference between MAP me-
dian concentration (M/F=125.83/123) and 
PP (M/F=56/62mmHg) was not statisti-
cally significant (p>0.01). 
Conclusion. Currently no gold standard 
technique is available to measure the CBP. 
Future studies should address that the cuff 
method could be a promising device in 
every day practice for this high risk popu-
lation. 
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INTRODUCTION
Despite measuring the blood pressure with 
a cuff and sphygmomanometer in the bra-
chial artery, we have been accepting it as 
an important marker for the prediction of 
future cardiovascular, cerebrovascular and 
renal disease risk1. The brachial pressure 
(BP) values vary numerously in individu-
als from that of the central (aortic) blood 
pressure2. Many studies described that the 
increase in central blood pressure (CBP) 
is an indicator of future cardiovascular or 
other target organ damage3. The brachial 
and central pressures respond differently 
to different drugs, with central pressure 
being more accurate and specific than the 
brachial one4. The measurement of bra-
chial pressure has been passed on for ages, 
but the central pressure detection could 
only be possible with invasive techniques, 
until recently non-invasive and modern 
technology was introduced into the clin-
ics5. The systolic pressure amplification 
phenomenon occurs due to the increase in 
the arterial stiffness shifting way from the 
heart. As the pressure waves travel from 
highly elastic central arteries to that of 
stiffened brachial arteries, the upper por-
tion of the wave narrows, followed by the 
increase in the systolic blood pressure6. 
The peripheral arteries are muscular and 
not distensible whereas the central arteries 
are made of elastin fibres. The arterial walls 
of the large arteries permit blood filling 
during systole distending and push blood 
flow in a steady flow during diastole as the 
artery recoils. As a result the thoracic and 
ascending aorta is less stiff and distal arter-
ies like the tibial are stiffer7. 
Arterial stiffness rapidly increases in the 
limb vessels as the move away from the 
heart, this leads to a larger wave with great-
er systolic blood pressure. This results in 
making the brachial systolic BP and pulse 
pressure greater than the central pressure 
in young individuals, whereas the diastolic 
BP is in the normal range. The pulse pres-
sure (PP) is the difference between the sys-
tolic and diastolic pressure of the respec-
tive artery measured.  
Pulse wave velocity (PWV) is the speed 
at which the pressure waveform travels 
along the aorta and large arteries, during 
each cardiac cycle8. PWV is considered 
the gold standard for measuring the arte-
rial stiffness. Compared with the general 
population, cardiorenal morbidity is much 
higher in patients with resistant hyperten-
sion (RH).  We investigated the value of 
CBP and pulse wave velocity in a group of 
RH patients.
The primary objective of this study was 
to determine the value of PWV in resist-
ant hypertension using for the first time a 
non-invasive measurement. The secondary 
goal was quantification and comparison of 
PWV according to sex.
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PATIENTS AND METHODS
The study included 80 patients with resist-
ant hypertension (RH) without acute heart 
failure, acute coronary disease and with-
out chronic kidney disease (eGFR <60ml/
min/1.73m2). The study population con-
sisted of patients enrolled in Registar of 
RH and is an ongoing prospective single-
center cohort study at the University hos-
pital Merkur, Zagreb. The study included 
only patients from June 2017 to January 
2018. All RH patients gave their written 
informed consent. The study was approved 
by the ethics committee.
Resistant hypertension is defined as fail-
ure to diminish blood pressure values to 
<140/90 mmHg (<140/85mmHg for dia-
betic patients) with a lifestyle method and 
prescription of at least three antihyperten-
sive drugs in optimal doses, including a 
diuretic, or when patients use four or more 
antihypertensive drugs regardless of blood 
pressure control9.  The following classes 
of medications were used: in all patients 
angiotensin-converting enzyme (ACE) in-
hibitors or angiotensin II receptor blockers 
(ARBs), calcium channel blockers (CCBs) 
and diuretics (we prefere combinations 
like ACEI+CCB+diuretic). In 75 % beta 
blockers, in 40% sympatholytics, and po-
tassium sparing diuretic in 30 %. 
The measurement of the central blood 
pressure detection was evaluated with 
new non-invasive techniques10. We used 
brachial pressure waveforms of superficial 
arteries (almost identical to those obtained 
intra-arterially) 11. This arm cuff based 
method makes use of a transfer function-
like method with the ARCSolver algo-
rithm built in the Mobil-o-graph10. An 
appropriate cuff-size we used to avoid poor 
blood pressure measurement after rest of 
5 minutes.  In all patients, we measured 
central blood pressure and PWV several 
times in an ideal environment (patients 
sat calmly and quietly). The pulse wave ve-
locity (PWV, m/s), mean arterial pressure 
(MAP, mmHg, normal value <105), age of 
vessels (older than biological age or same 
as  the biological age, years), pulse pressure 
(PP, mmHg, normal value <60), central 
blood pressure (CBP, normal value<130/90 
mmHg), and brachial pressure (BP, normal 
value <140/90 mmHg) were evaluated us-
ing the noninvasive Agedio B900 device 
(IEM, Stolberg, Germany) 10,11.
The statistical analysis was made using the 
statistical program Statistics (version 13.1). 
Descriptive data analysis was performed 
for all attributes.
RESULTS 
The median age of patients with RH was 
58.75 years (SD-15.3). A minority of pa-
tients, 27, (35%) were male and were 
younger than their female counterparts 
(53.9 years). BP and CBP were elevated 
in all RH patients (53 F/27M). The dif-
ference between median concentration 
of BP (145.9/90.52mmHg, F =146.4/89.5, 
M=145/92) and CBP (132.16/91.78mmHg, 
F=132/90, M 131/94) was statistically sig-
nificant for systolic BP (p<0.01). The mean 
value of the total measured PWV value was 
higher than reference for age in all RH and 
was 8.84 m/s. The mean value of PP and 
MAP was higher than reference (60.11 and 
123.87 mmHg). The difference between 
sex was statistically significant for PWV 
(M/F= 8.1/9.2m/s, p<0.01). In all patients 
age of vessels was older than biological age 
for >6 years. The difference between MAP 
median concentration (M/F=125.83/123) 
and PP (M/F=56/62mmHg) was not statis-
tically significant (p>0.01). 
All data are in tables.                                      
Table 1. The value of brachial, central blood pressure, pulse wave velocity, pulse pressure, mean arterial pressure and age of vessels in total 
(80) patients with resistant hypertension 
Age (y) BP-syst BP-dias CBP-sys CBP-dias PWV Age of vessels PP MAP
Avg-  57.75 145.9 90.52 132.16 91.78 8.84 6.11 60.11 123.87
SD-15.3 21.29 12.85 19.6 13.43 2.25 2.53 21.81 11.84
BP syst=systolic brachial pressure (mmHg), BP dias=diastolic brachial pressure (mmHg),  CBP syst= systolic central blood pressure 
(mmHg),  CBP dias= diastolic central blood pressure (mmHg), PWV=pulse wave velocity (m/s). PP= pulse pressure (mmHg), MAP= 
mean arterial pressure (mmHg) 
Table 2. The value of brachial, central blood pressure, pulse wave velocity, pulse pressure, mean arterial pressure and age of vessels in male 
(N=27) patients with resistant hypertension
Age (years) BP-syst BP-dias CBP-sys CBP-dias PWV Age of vessels PP MAP
Avg-53.29 145 92.66 131.11 94.33 8.12 6.17 56.41 125.83
SD-14.53 24.25 14.35 20.5 15.49 1.97 2.38 24.51 12.64
BP syst=systolic brachial pressure (mmHg), BP dias=diastolic brachial pressure (mmHg),  CBP syst= systolic central blood pressure 
(mmHg),  CBP dias= diastolic central blood pressure (mmHg), PWV=pulse wave velocity (m/s). PP= pulse pressure (mmHg), MAP= 
mean arterial pressure (mmHg) 
Table 3. The value of brachial, central blood pressure, pulse wave velocity, pulse pressure, mean arterial pressure and age of vessels in 
female (N=53) patients with resistant hypertension 
Age BP-syst BP-dias CBP-sys CBP-dias PWV Age of vessels Pulse pressure MAP
AVG-60.01 146.41 89.49 132.69 90.49 9.20 6.08 62.1 123
SD-15.27 19.84 12.072 18.91 12.20 2.31 2.62 20.19 11.60
BP syst=systolic brachial pressure (mmHg), BP dias=diastolic brachial pressure (mmHg),  CBP syst= systolic central blood pressure 
(mmHg),  CBP dias= diastolic central blood pressure (mmHg), PWV=pulse wave velocity (m/s). PP= pulse pressure (mmHg), MAP= 
mean arterial pressure (mmHg) 
30   |  SIGNA VITAE
DISCUSSION
Patients with resistant hypertension are 
presented with a long-standing history of 
poorly controlled hypertension9. Inaccu-
rate blood pressure measurement is not 
uncommon; it occurs when patients are 
not instructed to sit calmly and quietly, 
and when the cuff is too small12. In this 
study an appropriate cuff-size was used 
to avoid poor blood pressure measure-
ment. In accordance with the new original 
article from the Netherlands, that in hy-
pertensive patients presence of controlled 
(BP<140/90mmHg) or uncontrolled 
(BP>140/90mmHg) resistant hypertension 
is related to an increased risk of cardiovas-
cular mortality and all-cause mortality13, 
we measured PWV. We have proved for 
the first time that RH patients have higher 
PWV (than according to age), and this re-
search confirmed the difference between 
sex. In female patients, menopause status 
influences arterial stiffness, but mecha-
nisms are undefined. We have confirmed 
that a measurement finding is not random 
because we measured PWV and CBP sev-
eral times. Due to higher cardiovascular 
risk, resistant hypertension is serious and 
requires special diagnosis and treatment 
by a multidisciplinary team14. It is of high 
importance that the evaluation of a patient 
with RH includes on the first visit not only 
24-hours ambulatory monitoring of blood 
pressure (AMBP) but also measurement 
of CBP and PWV. This cuff-based device 
is usable without specific training and is 
adapted to ambulatory use.
CONCLUSION
Currently no gold standard technique is 
available to measure the central blood 
pressure. The non invasive cuff method is 
more promising and needs further evalu-
ation. Future studies should address that 
the cuff method could be a promising 
device in every day practice for this high 
risk population RH. Targeting PWV from 
a therapeutic perspective might slow the 
progression of cardiovascular remodeling.
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